Protocol Ledger

NCT06660394 · Phase III · ACTIVE NOT RECRUITING

A Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS)

Interventional Phase III clinical trial protocol NCT06660394 sponsored by Longboard Pharmaceuticals in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-09-25 Enrollment: 108 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT06660394
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)108 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06660394
Protocol FieldVerified Registry Value
NCT IdentifierNCT06660394
Consolidated Lead SponsorLongboard Pharmaceuticals
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase III
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment108 participants (ACTUAL)
Registered Start Date2024-09-25
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI